Locally advanced rectal carcinoma continues to be a major oncologic problem in the United States with approximately 40,000 new cases diagnosed in 2011. For stage II/III rectal carcinoma, adjuvant chemoradiation(1-3) and total mesorectal excision (TME) (4, 5)represent the major treatment advances that have increased cure rates over the past 30 years.